LPCN logo

Lipocine (LPCN) Company Overview

Profile

Full Name:

Lipocine Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

October 22, 2013

Indexes:

Not included

Description:

Lipocine Inc. (LPCN) is a biopharmaceutical company focused on developing innovative treatments for hormone-related conditions. They specialize in drug delivery systems, particularly for testosterone replacement therapy, aiming to improve patient outcomes and quality of life through their advanced formulations.

Key Details

Price

$3.50

Annual Revenue

-$2.85 M(-670.16% YoY)

Annual EPS

-$3.14(-46.05% YoY)

Annual ROE

-58.40%

Beta

0.51

Events Calendar

Earnings

Next earnings date:

Mar 7, 2025

Recent quarterly earnings:

Nov 7, 2024

Recent annual earnings:

Mar 7, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

May 12, 2023

Analyst ratings

Recent major analysts updates

Jul 27, 23 Cantor Fitzgerald
Overweight
Aug 26, 21 HC Wainwright & Co.
Buy
Jun 24, 21 Cantor Fitzgerald
Overweight
May 27, 21 HC Wainwright & Co.
Buy
Dec 10, 20 Ladenburg Thalmann
Buy
May 27, 20 HC Wainwright & Co.
Buy
Mar 29, 18 Seaport Global
Buy
Feb 27, 18 Empire Asset Management
Buy
Jan 11, 18 Canaccord Genuity
Hold
Oct 7, 16 HC Wainwright & Co.
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

Lipocine Receives Updated Regulatory Guidance on LPCN 1154
Lipocine Receives Updated Regulatory Guidance on LPCN 1154
Lipocine Receives Updated Regulatory Guidance on LPCN 1154
LPCN
prnewswire.comFebruary 6, 2025

SALT LAKE CITY , Feb. 6, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced receipt of revised regulatory guidance for LPCN 1154 which the Company is developing for postpartum depression (PPD) treatment.  As previously disclosed, the Company was scheduled to meet with the U.S. Food and Drug Administration (FDA or the Division) in Q1 2025 to discuss the NDA submission package of LPCN 1154.

Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session
Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session
Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session
LPCN
prnewswire.comNovember 18, 2024

SALT LAKE CITY , Nov. 18, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced the publication and discussion of a manuscript "Oral LPCN 1148 Improves Sarcopenia and Hepatic Encephalopathy in Male Patients with Cirrhosis: a randomized, placebo-controlled Phase 2 trial" in the journal Hepatology and discussion at The Liver Meeting (AASLD) 2024 Editor's Cut: Clinical Study Session held on November 16, 2024. LPCN 1148 is targeted to be a "First in Class" product candidate with a novel mechanism of action for overt hepatic encephalopathy and sarcopenia indications.

Lipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek®
Lipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek®
Lipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek®
LPCN
prnewswire.comSeptember 5, 2024

Study evaluated LPCN 2401 in participants with obesity (BMI ≥30) and participants with BMI ≥27 with at least one weight-related comorbidity SALT LAKE CITY , Sept. 5, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced that a poster featuring Phase 2 data on LPCN 2401 will be presented at the Obesity Society's Annual ObesityWeek® conference to be held November 3 – 6, 2024 in San Antonio, TX.

Lipocine to Present at the H.C. Wainwright Annual NASH Investor Conference
Lipocine to Present at the H.C. Wainwright Annual NASH Investor Conference
Lipocine to Present at the H.C. Wainwright Annual NASH Investor Conference
LPCN
PRNewsWireOctober 23, 2023

SALT LAKE CITY , Oct. 23, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that it will present and meet with investors at the H.C. Wainwright 7th Annual NASH Investor Conference, taking place virtually October 24, 2023.

Why Is Lipocine (LPCN) Stock Up 32% Today?
Why Is Lipocine (LPCN) Stock Up 32% Today?
Why Is Lipocine (LPCN) Stock Up 32% Today?
LPCN
InvestorPlaceJuly 27, 2023

Lipocine (NASDAQ: LPCN ) stock is rising higher on Thursday after the company released positive results from a Phase 2 clinical trial. That trail covers the use of LPCN 1148 as a treatment for patients suffering from cirrhosis.

FAQ

  • What is the ticker symbol for Lipocine?
  • Does Lipocine pay dividends?
  • What sector is Lipocine in?
  • What industry is Lipocine in?
  • What country is Lipocine based in?
  • When did Lipocine go public?
  • Is Lipocine in the S&P 500?
  • Is Lipocine in the NASDAQ 100?
  • Is Lipocine in the Dow Jones?
  • When was Lipocine's last earnings report?
  • When does Lipocine report earnings?
  • Should I buy Lipocine stock now?

What is the ticker symbol for Lipocine?

The ticker symbol for Lipocine is NASDAQ:LPCN

Does Lipocine pay dividends?

No, Lipocine does not pay dividends

What sector is Lipocine in?

Lipocine is in the Healthcare sector

What industry is Lipocine in?

Lipocine is in the Biotechnology industry

What country is Lipocine based in?

Lipocine is headquartered in United States

When did Lipocine go public?

Lipocine's initial public offering (IPO) was on October 22, 2013

Is Lipocine in the S&P 500?

No, Lipocine is not included in the S&P 500 index

Is Lipocine in the NASDAQ 100?

No, Lipocine is not included in the NASDAQ 100 index

Is Lipocine in the Dow Jones?

No, Lipocine is not included in the Dow Jones index

When was Lipocine's last earnings report?

Lipocine's most recent earnings report was on Nov 7, 2024

When does Lipocine report earnings?

The next expected earnings date for Lipocine is Mar 7, 2025

Should I buy Lipocine stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions